




RealRate

PHARMACEUTICAL 2021

NEKTAR THERAPEUTICS
Rank 163 of 409

NEKTAR®



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

NEKTAR THERAPEUTICS Rank 163 of 409

NEKTAR

The relative strengths and weaknesses of NEKTAR THERAPEUTICS are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEKTAR THERAPEUTICS compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 52% points. The greatest weakness of NEKTAR THERAPEUTICS is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is -62%, being 293% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,138,005
Cost of Goods Sold	19,477
Intangible Assets	76,501
Liabilities, Current	115,779
Liabilities, Non-Current	145,353
Other Assets	264,599
Other Compr. Net Income	-1,290
Other Expenses	45,682
Other Liabilities	200,340
Other Net Income	-18,836
Property and Equipment	59,662
Research and Development	408,678
Revenues	152,915
Selling, General and Administrative Expense	104,682

Output Variable	Value in 1000 USD
Assets	1,538,767
Liabilities	461,472
Expenses	578,519
Stockholders Equity	1,077,295
Net Income	-444,440
Comprehensive Net Income	-445,085
Economic Capital Ratio	-62%

